Native human
osteoprotegerin amino acid sequence, N-terminal signaling peptide (gray) 1 mnkllccalv fldisikwtt qetfppkylh ydeetshqll cdkcppgtyl kqhctakwkt 61 vcapcpdhyy tdswhtsdec lycspvckel qyvkqecnrt hnrvceckeg ryleiefclk 121 hrscppgfgv vqagtpernt vckrcpdgff snetsskapc rkhtncsvfg llltqkgnat 181 hdnicsgnse stqkcgidvt lceeaffrfa vptkftpnwl svlvdnlpgt kvnaesveri 241 krqhssqeqt fqllklwkhq nkdqdivkki iqdidlcens vqrhighanl tfeqlrslme 301 slpgkkvgae diektikack psdqilklls lwrikngdqd tlkglmhalk hsktyhfpkt 361 vtqslkktir flhsftmykl yqklflemig nqvqsvkisc 1
Prognostic significance of serum
osteoprotegerin levels in patients with bladder carcinoma," Cancer, vol.
Correlates of
osteoprotegerin levels in women and men.
STOCKHOLM -- Higher blood levels of the bone hormone
osteoprotegerin are associated with an increased long-term risk of death in patients with chronic heart failure, according to Dr.
The effects of estrogen on bone mediated by various cytokines such as decreased M-CSF, GM-CSF, TNF-[alpha], IL-I, IL-6, PGE2 and increased levels of TGF-[beta] or
osteoprotegerin or by decreasing receptor activating nuclear factor k-[beta] ligand (RANKL) in the bone marrow microenvironment [8,9,10].
Studies reported increased cytokine levels (IL, TNF) and increased
osteoprotegerin levels, leading to deregulation of RANKL-RANK interaction.
The function of the latter cells is regulated by a family of proteins that include receptor activator of nuclear factor κ-B (RANK), RANK ligand (RANKL) and
osteoprotegerin (OPG).
Proinflammatory cytokines and receptor activator of nuclear factor kappaBligand/
osteoprotegerin associated with bone deterioration in patients with Crohn's disease.
Reprinted from Curr Opin Pharmacol, Vol 5, Kostenuik P J,
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength, pp 618-625.
In the new study, the researchers from University of Edinburgh focused on a protein called
osteoprotegerin (OPG) in coeliac disease patients.
Increased expression of receptor activator of NF- B ligand (RANKL), its receptor RANK and its decoy receptor
osteoprotegerin in the colon of Crohn's disease patients.
IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and
osteoprotegerin ligand and prevents bone erosion.
